Bausch + Lomb Q3 revenue $1.28B (+7% YoY); narrows FY adjusted EBITDA guidance to $870M-$910M

Bausch & Lomb Corp

2025-Q3 EPS reported -$0.85 revenue$3,696,000,000

Revenue $1.281B, up 7% reported (6% constant currency); Vision Care +8%, Surgical +4%, Pharmaceuticals +8%.
GAAP net loss $28M ($0.08 loss per share) vs net income $4M ($0.01 EPS) in Q3 2024.
Adjusted EBITDA excluding acquired IPR&D $243M, up from $227M; adjusted EPS excl. IPR&D $0.18 vs $0.17.
FY 2025 revenue guidance reaffirmed at $5.05B-$5.15B; adjusted EBITDA guidance low end raised $10M to $870M-$910M.
Cash from operations $137M vs $154M; CEO cites pipeline and investor day as upcoming catalysts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.